Long-term data gathered from the TRANSCEND NHL trial have shown that this treatment approach can significantly improve survival.

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, affecting tens of thousands of people each year in the U.S. While many patients respond well to initial treatment ...

Swedish cancer patients treated with CAR T-cell therapy show better survival rates and fewer side effects than seen in ...

30 Other toxic effects were graded with the use of National Cancer Institute Common Terminology ... Most patients had subtypes of large B-cell lymphoma, including 8 with diffuse large B-cell ...

A phase I study of a next-generation CAR T cell ... lymphoma. A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to ...

You've learned that you have diffuse large B-cell lymphoma (DLBCL). What happens now? A cancer diagnosis can feel overwhelming. You might not know what to do first. Start by having a conversation ...

B-cell lymphoma is a type of blood cancer that affects the B lymphocytes of the immune system. They usually arise in the lymph nodes or in other lymphoid tissue, such as the spleen, bone marrow ...

You see it in marginal zone lymphoma, follicular lymphoma, CLL, mantle cell and diffuse large B cell lymphoma. “We focused initially on DLBCL and mantle because those are ones where there’s a ...

Blood: "CAR T-cells as a second-line therapy of large B-cell lymphoma: A paradigm shift?" National Cancer Institute: "Should CAR T Cells Be Used Earlier in People with Non-Hodgkin Lymphoma?" ...

NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL ... recently demonstrated a 64% relapse-free probability and a 43% probability ...

NICE has backed Celgene’s Revlimid for routine NHS use in another indication, follicular lymphoma, as part of a chemotherapy-free regimen ... bust in diffuse large B-cell lymphoma (DLBCL).